Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  Disease Landscape and Forecast Insights

Obesity / Overweight – Epidemiology – Epidemiology Dashboard

Login to access report north_east
Contact sales account_box

Clarivate Epidemiology’s coverage of obesity / overweight comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the total obesity / overweight prevalent cases for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the mature markets and Europe, and 10 years for the other countries we cover.

All forecast data are available on Clarivate’s Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

Clarivate Epidemiology’s obesity / overweight forecast answers the following questions:

  • How will changes in the levels of exposure to known risk or protective factors affect the number of people living with a diagnosis of obesity / overweight and the number of new diagnoses of obesity / overweight?
  • Of all people diagnosed with obesity / overweight, how many in each country across the major mature pharmaceutical markets are drug-treated?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of obesity / overweight over the forecast period?

In addition to the total obesity prevalent cases for each forecast year, Clarivate Epidemiology provides at least 10 years of forecast data for the following obesity / overweight subpopulations:

  • Total overweight prevalent cases
  • Total obesity prevalent cases after effective usage of GLP-1RAs
  • Drug and non-drug-eligible overweight prevalent cases
  • Severity 
  • Diagnosed and undiagnosed prevalent cases
  • Diagnosed drug and non-drug-treated obesity prevalent cases
  • Diagnosed drug and non-drug-eligible overweight prevalent cases

Note: Coverage may vary by country.

Table of contents

Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Major Depressive Disorder (DSM-V) – Current Treatment – Treatment Algorithms: Claims Data Analysis – Major Depressive Disorder (US)
Major depressive disorder (MDD) is a condition heavily treated with an array of drug classes. Although the MDD drug market is dominated by generic therapies, the heterogeneous response of MDD…
north_east
Report
Hidradenitis Suppurativa – Current Treatment – Treatment Algorithms: Claims Data Analysis – Hidradenitis Suppurativa (US)
Hidradenitis suppurativa (HS) is a chronic, relapsing inflammatory disorder affecting hair follicles. It is characterized by the occurrence of inflamed and swollen lesions, which are typically…
north_east
Report
Epilepsy – Landscape & Forecast – Disease Landscape & Forecast (G7)
Epilepsy is a complex neurological disorder marked by recurrent seizures, affecting approximately 4.7 million people across the major markets, as reported by Clarivate Epidemiology. Given epilepsy…
north_east
Report
Biosimilars – Emerging Biosimilars – Emerging Biosimilars Landscape
The Emerging Biosimilars Landscape offers extensive coverage of the global biosimilars development landscape. We track over 722 currently available and novel biosimilar products, detailing…
north_east
Report
Psoriasis – Landscape & Forecast – Disease Landscape & Forecast (G7)
The psoriasis therapy market has become increasingly lucrative due to the growing use of targeted agents. The newer IL-17 and IL-23 inhibitors (e.g., Eli Lilly’s Taltz, Johnson & Johnson…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east